Attached files
| file | filename |
|---|---|
| EX-10.3 - EXHIBIT 10.3 - Zander Therapeutics, Inc | ex10_3.htm |
| EX-10.2 - EXHIBIT 10.2 - Zander Therapeutics, Inc | ex10_2.htm |
| 8-K - FORM 8-K - Zander Therapeutics, Inc | zander070618form8k.htm |
ENTEST GROUP, INC. AND ZANDER THERAPEUTICS, INC. AGREEMENT
Zander Therapeutics, Inc. agrees to purchase 3,500,000 Series A preferred Shares of Regen Biopharma, Inc. (“Shares”) from Entest Group, Inc. (“Owner”) for the price of $35,000 USD cash. Latest closing price for these shares is .028 US$ per share or total value of $98,000.
Owner acknowledges that Shares are free of any encumbrances and able to be transferred to Zander Therapeutics, Inc.
Signed in Agreement:
| /s/David Koos | ||
| By: David Koos, CEO | ||
| ENTEST GROUP,INC. | ||
| /s/David Koos | ||
| By: David Koos, CEO | ||
| ZANDER THERAPEUTICS, INC. |